Erythropoietin and diabetes mellitus

Maiese, Kenneth

doi:10.4239/wjd.v6.i14.1259

Cited by 48 publications

(44 citation statements)

References 253 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…EPO has the capacity to offer protection against a number of disease entities (208–212) as well as enhanced biological activity (213, 214). For example, EPO has been reported to improve clinical outcome during development (215), neurodegenerative disorders (216), stroke (217–222), aging (223), TBI (32, 224), vascular disease (217–222), depression (208, 225), and metabolic disturbances (63, 211, 226, 227). …”

Section: Erythropoietin and The Modulation Of Mtormentioning

confidence: 99%

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Maiese¹

2016

CNR

Self Cite

View full text Add to dashboard Cite

Life expectancy continues to increase throughout the world, but is accompanied by a rise in the incidence of non-communicable diseases. As a result, the benefits of an increased lifespan can be limited by aging-related disorders that necessitate new directives for the development of effective and safe treatment modalities. With this objective, the mechanistic target of rapamycin (mTOR), a 289-kDa serine/threonine protein, and its related pathways of mTOR Complex 1 (mTORC1), mTOR Complex 2 (mTORC2), proline rich Akt substrate 40 kDa (PRAS40), AMP activated protein kinase (AMPK), Wnt signaling, and silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae) (SIRT1), have generated significant excitement for furthering novel therapies applicable to multiple systems of the body. Yet, the biological and clinical outcome of these pathways can be complex especially with oversight of cell death mechanisms that involve apoptosis and autophagy. Growth factors, and in particular erythropoietin (EPO), are one avenue under consideration to implement control over cell death pathways since EPO can offer potential treatment for multiple disease entities and is intimately dependent upon mTOR signaling. In experimental and clinical studies, EPO appears to have significant efficacy in treating several disorders including those involving the developing brain. However, in mature populations that are affected by aging-related disorders, the direction for the use of EPO to treat clinical disease is less clear that may be dependent upon a number of factors including the understanding of mTOR signaling. Continued focus upon the regulatory elements that control EPO and mTOR signaling could generate critical insights for targeting a broad range of clinical maladies.

show abstract

Section: Erythropoietin and The Modulation Of Mtormentioning

confidence: 99%

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Maiese¹

2016

CNR

Self Cite

View full text Add to dashboard Cite

show abstract

“…EPO expression can be influenced by changes in oxygen tension and not by the concentration of red blood cells [28,34,39]. Expression of EPO also may be promoted by stimuli that are not related to hypoxia [40]. For example, agents that block inflammation in cerebral microglia have been recently shown to lead to the release of EPO [41] and xenon anesthesia in cardiac surgery can result in elevated EPO serum concentrations [42].…”

Section: Erythropoietin and Traumatic Brain Injury: Translating Expermentioning

confidence: 99%

Charting a course for erythropoietin in traumatic brain injury

Maiese¹

2016

J Transl Sci

Self Cite

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a severe public health problem that impacts more than four million individuals in the United States alone and is increasing in incidence on a global scale. Importantly, TBI can result in acute as well as chronic impairments for the nervous system leaving individuals with chronic disability and in instances of severe trauma, death becomes the ultimate outcome. In light of the significant negative health consequences of TBI, multiple therapeutic strategies are under investigation, but those focusing upon the cytokine and growth factor erythropoietin (EPO) have generated a great degree of enthusiasm. EPO can control cell death pathways tied to apoptosis and autophagy as well oversees processes that affect cellular longevity and aging. In vitro studies and experimental animal models of TBI have shown that EPO can restore axonal integrity, promote cellular proliferation, reduce brain edema, and preserve cellular energy homeostasis and mitochondrial function. Clinical studies for neurodegenerative disorders that involve loss of cognition or developmental brain injury support a positive role for EPO to prevent or reduce injury in the nervous system. However, recent clinical trials with EPO and TBI have not produced such clear conclusions. Further clinical studies are warranted to address the potential efficacy of EPO during TBI, the concerns with the onset, extent, and duration of EPO therapeutic strategies, and to focus upon the specific downstream pathways controlled by EPO such as protein kinase B (Akt), mechanistic target of rapamycin (mTOR), AMP activated protein kinase (AMPK), sirtuins, wingless pathways, and forkhead transcription factors for improved precision against the detrimental effects of TBI. KeywordsAkt; Alzheimer's disease; apoptosis; autophagy; erythropoietin; forkhead; mTOR; Parkinson's disease; neurodegeneration; programmed cell death; sirtuins; traumatic brain injury; Wnt Erythropoietin and traumatic brain injury: Translating experimental success into clinical efficacyIn more than 30 million individuals throughout the world, both acute and chronic neurodegenerative disorders can result in significant disability as well as eventual death [1,2]. Chronic neurodegenerative diseases, such as Parkinson's disease (PD) [3,4], can affect approximately 4 percent of individuals over the age of sixty. In addition, the number ofThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For the sporadic form of AD, approximately 10 percent of the global population over the age of sixty-five is affected [3,5]. Over the next two decades, it is estimated that the number of those suffering from AD will increase significantly to more than 30 million individuals [6][7][8]. HHS Public AccessFor acute neurodegenerative injury, disorders such as stroke can impact almost 800,000 individuals every year with a...

show abstract

“…It is worth mentioning that EPO due to its anti-apoptotic and tissue protective effects has long been used in treatment of chronic anemia (16) , myocardial infraction (17) , diabetes mellitus (18) , spinal cord injury (19) , acute lung injury (20) . Relatively recent studies showed that EPO can increase the VEGF expression in the injury sites, promotes new vessels formation and promptly heal wounds (20) .…”

Section: Introductionmentioning

confidence: 99%

Effects of Erythropoietin on The Healing of Calvarial Bone Defect

Ahmed

Elmagd

Khairy

et al. 2019

Egyptian Dental Journal

View full text Add to dashboard Cite

Objectives To evaluate the effect of a single-dose local administration versus the systemic administration of Erythropoietin on bone healing in calvarial bone defectsMaterial & Methods Critical-size cranial osteotomy defects were created in 30 rabbits. The animals were randomly divided into 3 groups. The animals were randomly divided into 3 groups (n= 10 animals in each group). In the Group I, the bone defect was only filled with a collagen sponge soaked with erythropoietin. In the Group II, it was filled with a collagen sponge and erythropoietin injected systemically. While in the Group III, the defect was filled with a collagen sponge. The groups were further split in two for euthanasia 10-and 21-days post-surgery. New bone formation and neovascularization were evaluated by hematoxylin-eosin. For the 10-days samples, all the groups analyzed for area percent of blood vessels while on the 21-day samples, the area of new bone formation was calculated. Differences between groups were analyzed by one-way ANOVA.Results At 10 days post-surgery, the histological analysis showed that the erythropoietin Groups exhibited a significantly higher percentage of bone formation compared with the other Group. At 21 days post-surgery, a higher percentage of new bone was observed in the erythropoietin group. ConclusionsThe results suggest that both local and systemic administration of erythropoietin hormone encouraged the bone healing in critical-size calvarial defects in Rabbits.

show abstract

Erythropoietin and diabetes mellitus

Cited by 48 publications

References 253 publications

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Erythropoietin and mTOR: A “One-Two Punch” for Aging-Related Disorders Accompanied by Enhanced Life Expectancy

Charting a course for erythropoietin in traumatic brain injury

Effects of Erythropoietin on The Healing of Calvarial Bone Defect

Contact Info

Product

Resources

About